This is a Phase II study for recurrent ovarian carcinoma platinum-sensitive and resistant tumors Folfox regimen.
Lead Sponsor
Enrollment
Start Date
Completion Date
Study Type
Official Title
Age Range
Sex
Inclusion Criteria: * ovarian carcinoma relapse Exclusion Criteria: * neurotoxicity grade III renal clearance \< 60 ml/min